Imaging in systemic amyloidosis
Open Access
- 29 July 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 107 (1), 41-56
- https://doi.org/10.1093/bmb/ldt021
Abstract
Diagnosis of systemic amyloidosis remains challenging. Histology, the current gold standard for diagnosis of amyloidosis provides limited information on the extent of the disease and is not useful for monitoring. Non-invasive imaging modalities offer an easy way to evaluate whole-body amyloid burden, accurately identify organ involvement, quantify and monitor disease progression and response to treatment. A literature search was performed using PubMed on the subjects of ‘amyloid imaging’, ‘SAP scintigraphy’, ‘imaging in cardiac amyloidosis’, ‘cardiac MRI’, ‘PET and amyloidosis’ and ‘nuclear imaging in amyloidosis’. 123I-SAP scintigraphy is the best and the only modality in routine clinical use for assessing the extent and distribution of visceral amyloid deposition in all types of amyloidosis. Echocardiography remains the most important tool for assessing cardiac amyloidosis but cardiac magnetic resonance imaging is becoming increasingly valuable. Bone-seeking tracers like 99mTc-DPD and pyrophosphate are beginning to have a role in imaging transthyretin cardiac amyloidosis. Specificity of each of the imaging modalities limits the utility of any one imaging method for all types of amyloidosis for all organs. 99mTc-DPD has a high sensitivity and specificity to cardiac transthyretin amyloid deposits and its role in early diagnosis of this condition is under investigation. Further studies are needed with 123I-mIBG to assess its utility in patients with early cardiac autonomic neuropathy. Positron emission tomography with tracers used for Alzheimer's disease imaging is an area of increasing interest in systemic amyloid imaging.Keywords
This publication has 37 references indexed in Scilit:
- A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosisNephrology Dialysis Transplantation, 2012
- Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of AmyloidosisAmyloid, 2012
- Outcome of autologous stem cell transplantation for AL amyloidosis in the UKBritish Journal of Haematology, 2006
- Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with AmyloidosisAmerican Journal Of Medicine, 2006
- AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantationAmyloid, 2002
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinThe Lancet, 2001
- The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patientsGut, 1998
- Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.JCI Insight, 1990
- Evaluation of Systemic Amyloidosis by Scintigraphy with123I-Labeled Serum Amyloid P ComponentNew England Journal of Medicine, 1990
- DIAGNOSTIC RADIONUCLIDE IMAGING OF AMYLOID: BIOLOGICAL TARGETING BY CIRCULATING HUMAN SERUM AMYLOID P COMPONENTThe Lancet, 1988